PMID- 24589312
OWN - NLM
STAT- MEDLINE
DCOM- 20150331
LR  - 20140808
IS  - 1747-0285 (Electronic)
IS  - 1747-0277 (Linking)
VI  - 84
IP  - 3
DP  - 2014 Sep
TI  - Immunocompatibility and toxicity studies of poly-L-lysine nanocapsules in 
      sprague-dawley rats for drug-delivery applications.
PG  - 292-9
LID - 10.1111/cbdd.12313 [doi]
AB  - Poly-L-Lysine (PLL) nanocapsules are the emerging drug-delivery vehicle for the 
      therapeutics of targeted diseases. The study was designed for the synthesis and 
      characterization of PLL nanocapsules and to know its immunocompatibility and 
      toxicity behavior for in vivo drug-delivery applications. Alteration in 
      hematologic parameters, immunomodulatory gene expression by RT-PCR studies, 
      toxicity markers status, immunoblotting of major inflammatory marker proteins, 
      and histopathologic studies from major tissues of rat after intravenous 
      administration of PLL nanocapsules after 30 days were assessed. In vivo toxicity 
      markers activity, hematologic parameters alteration, and RT-PCR analysis of 
      important immunomodulatory genes such as monocyte chemotactic protein-1(MCP 1), 
      tumor necrosis factor-alpha (TNF-alpha), Intercellular adhesion molecule-1 (ICAM-1), 
      and interleukin-6 (IL-6) showed least changes when compared with control. The 
      immunoblotting of major inflammatory markers such as cyclooxygenase-2 (COX-2), 
      lipo-oxygenase-15 (LOX-15), and nitric oxide synthase (NOS) found have least 
      expression showing the immunocompatibility of PLL nanocapsules. Histopathologic 
      studies of important tissues showed almost normal architecture after treatment 
      using different concentration of PLL nanocapsules after the experimental period. 
      The results showed a promising outcome and further confirmed the 
      immunocompatibility and non-toxicity of PLL nanocapsules in vivo for 
      drug-delivery applications.
CI  - (c) 2014 John Wiley & Sons A/S.
FAU - Ayyappan, Janeesh Plakkal
AU  - Ayyappan JP
AD  - Department of Biochemistry, University of Kerala, Kariavattom campus, Trivandrum, 
      695 581, Kerala, India.
FAU - Sami, Haider
AU  - Sami H
FAU - Rajalekshmi, Dhanya Chandrasekharan
AU  - Rajalekshmi DC
FAU - Sivakumar, Sri
AU  - Sivakumar S
FAU - Abraham, Annie
AU  - Abraham A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140519
PL  - England
TA  - Chem Biol Drug Des
JT  - Chemical biology & drug design
JID - 101262549
RN  - 0 (Biocompatible Materials)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-6)
RN  - 0 (Nanocapsules)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 25104-18-1 (Polylysine)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials/*chemistry/toxicity
MH  - Chemokine CCL2/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Interleukin-6/metabolism
MH  - Kidney/drug effects/pathology
MH  - Liver/drug effects/pathology
MH  - Lung/drug effects/pathology
MH  - Male
MH  - Nanocapsules/*chemistry/toxicity/ultrastructure
MH  - Nitric Oxide Synthase/metabolism
MH  - Polylysine/*chemistry/toxicity
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Silicon Dioxide/chemistry
MH  - Spleen/drug effects/pathology
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Poly-L-Lysine nanocapsules
OT  - immunocompatibility
OT  - immunomodulatory genes
OT  - inflammatory markers
EDAT- 2014/03/05 06:00
MHDA- 2015/04/01 06:00
CRDT- 2014/03/05 06:00
PHST- 2013/11/27 00:00 [received]
PHST- 2014/02/11 00:00 [revised]
PHST- 2014/02/13 00:00 [accepted]
PHST- 2014/03/05 06:00 [entrez]
PHST- 2014/03/05 06:00 [pubmed]
PHST- 2015/04/01 06:00 [medline]
AID - 10.1111/cbdd.12313 [doi]
PST - ppublish
SO  - Chem Biol Drug Des. 2014 Sep;84(3):292-9. doi: 10.1111/cbdd.12313. Epub 2014 May 
      19.